Investigating the Benefits of Adding a New Drug to Osteosarcoma Treatment

Recruiting · Phase 2/Phase 3 · High Grade Osteosarcoma and related conditions · 44 states

Check if I qualify View on ClinicalTrials.gov

About this trial

This study looks at how well cabozantinib works when added to standard chemotherapy for patients with newly diagnosed osteosarcoma. The goal is to see if this combination is safe and if it helps patients do better than just chemotherapy alone. Cabozantinib is a medicine that may help stop tumor growth by blocking signals that allow cancer cells to grow and form new blood vessels. The standard chemotherapy includes medicines like methotrexate, doxorubicin, and cisplatin.

The trial's ID number is NCT05691478. It is a Phase 2/3 study, which means it is looking at how well the treatment works and how safe it is. The trial is FDA-regulated, and it aims to include about 1,122 participants.

Who can join

This trial is open to men and women under 40 years old. Participants must have a confirmed diagnosis of high-grade osteosarcoma and meet certain health criteria. Those with both localized and metastatic disease are eligible. The trial team will confirm if you qualify to join.

Conditions

High Grade Osteosarcoma, Localized Osteosarcoma, Metastatic Osteosarcoma, Secondary Osteosarcoma

Age group

Child, Adult

Sex

All sexes

The study team makes the final call on eligibility.

What happens in the study

Participants will be placed in one of several groups by chance. Some will receive standard chemotherapy, while others will receive chemotherapy along with cabozantinib. The study includes different phases for both standard risk and high-risk patients, with various treatment plans involving cycles of chemotherapy and evaluations throughout the trial.